BROWN GREGORY B 4
4 · Aquestive Therapeutics, Inc. · Filed Jun 12, 2026
Research Summary
AI-generated summary of this filing
Aquestive (AQST) Director Gregory B. Brown Receives Award
What Happened
Gregory B. Brown, a director of Aquestive Therapeutics, was granted derivative securities (options) to acquire 50,500 shares on June 10, 2026. The grant shows a $0.00 acquisition price at issue (no cash paid at grant) and is reported as a derivative award rather than an open‑market purchase or sale.
Key Details
- Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (filed within the typical two-business‑day window).
- Transaction type/code: Grant / Award (derivative; code A).
- Amount: 50,500 options/derivative shares; reported price $0.00 at grant.
- Vesting: 100% of the underlying shares vest on June 10, 2027, subject to Dr. Brown’s continued service (per footnote).
- Shares owned after transaction: Not reported on the provided filing.
- No immediate sale or exercise reported.
Context
This is a compensation grant to a director (not an open‑market purchase or sale). For retail investors: such awards are common for executive and director compensation and do not by themselves indicate a buy or sell sentiment. The award vests only if Dr. Brown remains with the company through June 10, 2027.
Insider Transaction Report
- Award
Stock Option (Right to Purchase)
[F1]2026-06-10+50,500→ 50,500 totalExercise: $3.99From: 2027-06-10Exp: 2036-06-10→ Common Stock (50,500 underlying)
- 75,085
Common Stock
Footnotes (1)
- [F1]The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Dr. Brown's continuous service with the Issuer from the grant date through the applicable vesting date.